Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

NEW YORK, May 2, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

http://www.reportlinker.com/p0847304/Pharma-Leader-Series-Top-50-Generic-Drug-Manufacturers-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug

Report Details

Generic drugs - discover potentials and revenue prospects of companies, seeing what the future holds 

How are companies in the generics market performing? Visiongain's report gives you data, analyses and discussions for leading manufacturers of generic drugs.

That new study lets you assess prominent companies in the generics market from 2012 to 2022. See how companies worldwide are performing and where they are heading. 

There, you find analytical profiles for leading producers - activities, outlooks and prospects:• Teva Pharmaceutical Industries• Sandoz• Mylan• Actavis• Hospira• Watson• Abbott• Sanofi• Ranbaxy• Cipla• Aspen• Stada Arzneimittel• Coverage of 38 other leading companies from around the world.

See how generics manufacturers compare, finding out how they can compete from 2012. 

Our investigation gives you business research and analysis, including revenue forecasts to 2022. You discover commercial data, predictions and discussions for companies and the market in which they operate. 

Where is the generics market heading? Many opportunities exist, especially in Japan and developing countries. Generic substitution is rising in Europe and the US.

Also, which producers will expand beyond their domestic and regional markets to become global forces for the manufacturing and sales of generic drugs? As our study shows, there are many companies breaking into new markets and expanding generic product ranges. 

Complex generics, with high market entry barriers, and biosimilar (follow-on biologic/protein) products will transform the generics industry and pharma markets. Many opportunities exist for drug companies with biotechnological capabilities. Our report shows and explains.

The patent cliff will result in many more of the pharmaceutical industry's blockbusters being opened to generic competition. Which generic drug producers can best seize opportunities from 2012 to 2022? You find answers now in our study. 

Company analysis, revenue forecasts and discussions of industry prospects

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios and growth potential. You receive 215 tables and charts.

Ten ways Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:• Assess 50 leading generics producers, discovering their activities and outlooks• Discover market leaders in each region• Receive analyses of leading companies, seeing revenue forecasts to 2022• View a comparative analysis of generics players• Assess commercial prospects, market breakdowns and product offerings• Find existing revenues and operational data for leading companies• Review technological, regulatory and commercial developments, assessing trends and prospects• Analyse prospects for generic drug launches• Investigate competition and opportunities influencing revenues• Find out what will stimulate and restrain the industry and market.

There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Gain business research and analysis on generic drug makers now Our study is for everybody needing industry and market analyses for generic drug companies. You find data, trends and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6 

Table of Contents 1. Executive Summary

1.1 Overview of Findings

1.2 Chapter Breakdown 

1.3 Research and Analysis Methods

1.4 Scope of this Report

1.5 Overview: Top 50 Generic Drug Manufacturers

2. The Leading Generic Drug Manufacturer: Teva Pharmaceutical Industries, 2012-20222.1 Teva's Generics Business, 20122.2 Regional Sales for Teva Generics, 2010-20112.3 Teva's M&A Strategy, 20122.4 Growth Forecast for Teva, 2012-2022

3. The Leading Big Pharma Generic Drug Manufacturers, 2012-2022

3.1 Novartis (Sandoz), 2012

3.1.1 Novartis' Generics Business, 2012

3.1.2 Sales Breakdown for Novartis Generics, 2010-2011

3.1.3 Growth Strategy for Novartis Generics, 2012-2022

3.1.4 Growth Forecast for Novartis Generics, 2012-2022

3.2 Abbott Laboratories, 2012

3.2.1 Abbott's Generics Business, 2012

3.2.2 Abbott's Position in the Emerging Markets, 2012

3.2.3 Growth Forecast for Abbott Generics, 2012-2022

3.3 Pfizer, 2012

3.3.1 Pfizer's Generics Business, 2012

3.3.2 Pfizer's Generics Growth Strategy, 2012

3.3.3 Growth Forecast for Pfizer Generics, 2012-2022

3.4 Sanofi, 2012

3.4.1 Sanofi's Generics Business, 2012

3.4.2 Sanofi's Generics Growth Strategy, 2012

3.4.3 Growth Forecast for Sanofi Generics, 2012-2022

3.5 Takeda, 2012

3.5.1 Business Segments of Nycomed, 2011

4. The Leading North American Generic Drug Manufacturers, 2012-20224.1 Mylan, 20124.1.1 Mylan's Generics Business, 20124.1.2 Mylan's Regional Presence, 20124.1.3 Growth Forecast for Mylan Generics, 2012-20224.2 Hospira, 20124.2.1 Hospira's Generics Business, 20124.2.2 Hospira Growth Strategies, 20124.2.3 Growth Forecast for Hospira Generics, 2012-20224.3 Watson Pharmaceuticals, 20124.3.1 Watson's Generics Business, 20124.3.2 Watson's Growth Strategies, 20124.3.3 Growth Forecast for Watson Generics, 2012-20224.4 Par Pharmaceutical, 20124.4.1 Par's Generics Business, 20124.4.2 Par's Growth Strategy, 20124.4.3 Litigation Involving Par to 20124.5 Apotex, 20124.5.1 Apotex's Generics Business, 20124.5.2 Apotex in the Canadian Generics Market, 20124.5.3 Key Apotex Generic Launches, 20114.6 Impax Laboratories, 20124.6.1 Impax's Generics Business, 20124.7 Covidien (Mallinckrodt), 20124.7.1 Mallinckrodt Generics, 20124.7.2 Litigation Involving Mallinckrodt4.8 Pharmascience, 20124.8.1 Pharmascience's Generics Business, 20124.8.2 Pharmascience's Growth Strategies, 20124.9 Perrigo Company, 20124.9.1 Perrigo's Generics Business, 20124.9.2 Growth Prospects for Perrigo's Generics Business, 20124.10 Hi-Tech Pharmacal, 20124.10.1 Hi-Tech's Generics Business, 20124.10.2 Growth Prospects for Hi-Tech, 20124.11 Other North American Generics Companies, 2012

5. The Leading European Generic Drug Manufacturers, 2012-2022

5.1 Actavis, 2012

5.1.1 Actavis' Generics Business, 2012

5.1.2 Actavis' Generics Growth Strategy, 2012

5.1.3 Growth Forecast for Actavis Generics, 2012-2022

5.2 Fresenius Kabi, 2012

5.2.1 Fresenius Kabi's Generics Business, 2012

5.2.2 Growth Strategies for Fresenius Kabi, 2012

5.2.3 Growth Forecast for Fresenius Kabi Generics, 2012-2022

5.3 Stada Arzneimittel, 2012

5.3.1 Stada's Generics Business, 2012

5.3.2 Stada's Growth Prospects, 2012

5.3.3 Growth Forecast for Stada Arzneimittel Generics, 2012-2022

5.4 Gedeon Richter, 2012

5.4.1 Gedeon Richter's Generics Business, 2012

5.4.2 Regional Presence of Gedeon Richter, 2012

5.4.3 Growth Forecast for Gedeon Richter Generics, 2012-2022

5.5 Krka, 2012

5.5.1 Krka's Generics Business, 2012

5.5.2 Krka's Business Growth, 2012

5.5.3 Growth Forecast for Krka Generics, 2012-2022

5.6 Alapis, 2012

5.6.1 Alapis' Generics Business, 2012

5.6.2 Alapis and the Greek Economic Crisis, 2009-2012

5.7 Pharmstandard, 2012

5.7.1 Pharmstandard's Generics Business, 2012

5.7.2 Pharmstandard's Growth Prospects, 2012

5.8 Egis Pharmaceuticals, 2012

5.8.1 Egis' Generics Business, 2012

5.8.2 Egis' Business Strategy, 2012

5.9 Angelini, 2012

5.9.1 Angelini's Generics Business, 2012

5.10 Orion, 2012

5.10.1 Orion's Generics Business, 2012

5.10.2 Orion's Regional Strategy, 2012

5.11 Bilim Pharmaceuticals, 2012

5.11.1 Bilim's Generics Business, 2012

5.11.2 Growth Prospects for Bilim

5.12 Veropharm, 2012

5.12.1 Growth Prospects for Veropharm's Generics Business, 2012

5.13 Elpen Pharmaceutical, 2012

5.13.1 Elpen's Generics Business, 2012

5.14 Eastpharma, 2012

5.14.1 Eastpharma's Generics Business, 2012

5.15 Other European Generics Companies, 2012

6. The Leading Indian Generic Drug Manufacturers, 2012-20226.1 Ranbaxy Laboratories, 20126.1.1 Ranbaxy's Generics Business, 20126.1.2 Ranbaxy's Growth Ambitions, 20126.1.3 Growth Forecast for Ranbaxy Generics, 2012-20226.2 Cipla, 20126.2.1 Cipla's Generics Business, 20126.2.2 Cipla and Patent Controversies, 20126.2.3 Growth Forecast for Cipla Generics, 2012-20226.3 Dr. Reddy's Laboratories, 20126.3.1 Dr. Reddy's Generics Business, 20126.3.2 Dr. Reddy's Regional Focus, 2012 6.3.3 Growth Forecast for Dr. Reddy's Generics, 2012-20226.4 Sun Pharma, 20126.4.1 Sun's Generics Business, 2012 6.4.2 Sun's Exports, 2012 6.4.3 Growth Forecast for Sun Pharma Generics, 2012-20226.5 Lupin, 2012 6.5.1 Lupin's Generics Business, 2012 6.5.2 Lupin's Regional Expansion, 2012 6.5.3 Growth Forecast for Lupin Generics, 2012-20226.6 Wockhardt, 2012 6.6.1 Wockhardt's Generics Business, 20126.7 Aurobindo, 20126.7.1 Aurobindo's Generics Business, 20126.8 Zydus Cadila, 20126.8.1 Zydus Cadila's Generics Business, 2012 6.9 Biocon, 20126.9.1 Biocon's Generics Business, 20126.9.2 Biocon's Collaborations, 20126.10 Strides Arcolab, 2012 6.10.1 Strides' Generics Business, 20126.10.2 Strides' Business Partnerships, 20126.11 Glenmark Pharmaceutical, 20126.11.1 Glenmark's Generics Business, 2012 6.11.2 Future Business Direction for Glenmark, 20126.12 Other Indian Generics Manufacturers, 2012

7. The Leading Generic Drug Manufacturers in the Rest of the World, 2012-2022

7.1 Aspen Pharma, 2012

7.1.1 Aspen's Generics Business, 2012

7.1.2 Aspen's Regional Presence, 2012

7.1.3 Growth Forecast for Aspen Pharma Generics, 2012-2022

7.2 Hikma Pharmaceuticals, 2012

7.2.1 Hikma's Generics Business and Growth Prospects, 2012

7.3 Sawai Pharmaceutical, 2012

7.3.1 Sawai's Generics Business and Prospects, 2012

7.4 Nichi-Iko Pharmaceutical Co., 2012

7.4.1 Nichi-Iko's Generic Business and Prospects, 2012

7.5 Towa Pharmaceutical, 2012

7.5.1 Towa's Generics Business and Prospects, 2012

7.6 Nippon Chemiphar, 2012

7.6.1 Chemiphar's Generics Business and Prospects, 2012

7.7 LG Life Sciences, 2012

7.7.1 LG Life Sciences' Generics Business and Prospects, 2012

7.8 EMS Sigma, 2012

7.8.1 EMS Sigma's Generics Business and Prospects, 2012

7.9 Eurofarma, 2012

7.9.1 Eurofarma's Generics Business and Prospects, 2012

List of Tables Table 1.1 Top 50 Generic Pharmaceutical Manufacturers: Revenues ($m) and Ranking, 2010

Table 2.1 Teva Pharmaceutical Industries: Overview, 2010

Table 2.2 Top Ten Generics Sector M&A Deals (Teva Deals Highlighted), 2004-Q1 2012

Table 2.3 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 3.1 Novartis: Overview, 2010

Table 3.2 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 3.3 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 3.4 Abbott Laboratories: Overview, 2010

Table 3.5 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 3.6 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 3.7 Pfizer: Overview, 2010

Table 3.8 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 3.9 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 3.10 Sanofi: Overview, 2010

Table 3.11 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 3.12 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 3.13 Takeda: Overview, 2010

Table 4.1 Mylan: Overview, 2010

Table 4.2 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 4.3 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 4.4 Hospira: Overview, 2010

Table 4.5 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 4.6 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 4.7 Watson: Overview, 2010

Table 4.8 Some Key Watson Generic Products, 2012

Table 4.9 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 4.10 Watson: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 4.11 Par Pharmaceutical: Overview, 2010

Table 4.12 Apotex: Overview, 2010

Table 4.13 Impax Laboratories: Overview, 2010

Table 4.14 Covidien: Overview, 2010

Table 4.15 Mallinckrodt Covidien Speciality Generics: Some Key Product Families, 2012

Table 4.16 Pharmascience: Overview, 2010

Table 4.17 Pharmascience Product Dossiers Registered in One or More EU State, 2012

Table 4.18 Perrigo Company: Overview, 2010

Table 4.19 High-Tech Pharmacal: Overview, 2010

Table 4.20 Selected Other North American Generic Companies, 2012

Table 5.1 Actavis: Overview, 2010

Table 5.2 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 5.3 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 5.4 Fresenius Kabi: Overview, 2010

Table 5.5 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 5.6 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 5.7 Stada Arzneimittel: Overview, 2010

Table 5.8 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 5.9 Stada: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 5.10 Gedeon Richter: Overview, 2010

Table 5.11 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 5.12 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 5.13 Krka: Overview, 2010

Table 5.14 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 5.15 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 5.16 Alapis: Overview, 2010

Table 5.17 Pharmstandard: Overview, 2010

Table 5.18 Egis: Overview, 2010

Table 5.19 Angelini: Overview, 2010

Table 5.20 Italian Drug Reimbursement Classes, 2012

Table 5.21 Orion: Overview, 2010

Table 5.22 Bilim Pharmaceuticals: Overview, 2010

Table 5.23 Veropharm: Overview, 2010

Table 5.24 Elpen Pharmaceutical: Overview, 2010

Table 5.25 Leading Elpen Generics, 2011

Table 5.26 EastPharma Pharmaceutical: Overview, 2010

Table 5.27 Leading EastPharma Generics, 2011

Table 5.28 Selected Other European Generics Companies, 2012

Table 6.1 Ranbaxy: Overview, 2010

Table 6.2 Ranbaxy: Top 10 Products, 2010

Table 6.3 Ranbaxy: Top 10 Therapeutic Areas, 2010

Table 6.4 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 6.5 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 6.6 Cipla: Overview, 2010

Table 6.7 Cipla: Subsidiaries and Affiliates, 2010

Table 6.8 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 6.9 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 6.10 Dr. Reddy's: Overview, 2010

Table 6.11 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 6.12 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 6.13 Sun Pharma: Overview, 2010

Table 6.14 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 6.15 Sun Pharma: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 6.16 Lupin: Overview, 2010

Table 6.17 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 6.18 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 6.19 Wockhardt: Overview, 2010

Table 6.20 Aurobindo: Overview, 2010

Table 6.21 Zydus Cadila: Overview, 2010

Table 6.22 Biocon: Overview, 2010

Table 6.23 Strides Arcolab: Overview, 2010 

Table 6.24 Glenmark: Overview, 2010

Table 7.1 Aspen Pharma: Overview, 2010

Table 7.2 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2010-2015

Table 7.3 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2016-2022

Table 7.4 Hikma: Overview, 2010

Table 7.5 Sawai: Overview, 2010

Table 7.6 Nichi-Iko: Overview, 2010

Table 7.7 Towa: Overview, 2010

Table 7.8 Nippon Chemiphar: Overview, 2010

Table 7.9 LG Life Sciences: Overview, 2010

Table 7.10 EMS Sigma: Overview, 2010

Table 7.11 Eurofarma: Overview, 2010

List of Figures Figure 2.1 Teva Pharmaceutical Industries: Business Segments Revenue Breakdown (%), 2010

Figure 2.2 Teva Pharmaceutical Industries: Generic Sales ($m), Regional Breakdown, 2011

Figure 2.3 Teva Pharmaceutical Industries: Generic Sales ($m), Quarterly Breakdown, 2011

Figure 2.4 Teva Pharmaceutical Industries: Generic Revenues ($m), 2010-2015

Figure 2.5 Teva Pharmaceutical Industries: Generic Revenues ($m), 2016-2022

Figure 3.1 Novartis: Business Segments Revenue Breakdown (%), 2011

Figure 3.2 Novartis: Generic Revenue Breakdown (%), 2011

Figure 3.3 Novartis: Generic Revenues ($m), 2010-2015

Figure 3.4 Novartis: Generic Revenues ($m), 2016-2022

Figure 3.5 Abbott: Business Segments Revenue Breakdown (%), 2010

Figure 3.6 Abbott: Generic Revenues ($m), 2010-2015

Figure 3.7 Abbott: Generic Revenues ($m), 2016-2022

Figure 3.8 Pfizer: Business Segments Revenue Breakdown (%), 2010

Figure 3.9 Pfizer: Generic Revenues ($m), 2010-2015

Figure 3.10 Pfizer: Generic Revenues ($m), 2016-2022

Figure 3.11 Sanofi: Pharmaceutical Business Segments Revenue Breakdown (%), 2010

Figure 3.12 Sanofi: Generic Revenues ($m), 2010-2015

Figure 3.13 Sanofi: Generic Revenues ($m), 2016-2022

Figure 4.1 Mylan: Revenue Breakdown by Therapeutic Area (%), 2011

Figure 4.2 Mylan: Revenue Breakdown by Business Segment (%), 2011

Figure 4.3 Mylan: Generic Revenues ($m), 2010-2015

Figure 4.4 Mylan: Generic Revenues ($m), 2016-2022

Figure 4.5 Hospira: Revenue Breakdown by Business Segment (%), 2010

Figure 4.6 Hospira: Specialty Injectables Revenue Breakdown by Region (%), 2010

Figure 4.7 Hospira: Generic Revenues ($m), 2010-2015

Figure 4.8 Hospira: Generic Revenues ($m), 2016-2022

Figure 4.9 Watson: Revenue Breakdown by Business Segment (%), 2010

Figure 4.10 Watson: Generic Revenues ($m), 2010-2015

Figure 4.11 Watson: Generic Revenues ($m), 2016-2022

Figure 4.12 Par Generics: Revenue Breakdown by Customer (%), 2010

Figure 4.13 Generic Share in Canadian Market by Revenue (%), 2010

Figure 4.14 Generic Share in Canadian Market by Prescription Volume (%), 2005-2010

Figure 4.15 Impax Sales Channel Revenue Breakdown (%), 2010

Figure 4.16 Impax Generics: Revenue Breakdown by Customer (%), 2010

Figure 4.17 Perrigo Company: Revenue Breakdown by Business Segment (%), 2011

Figure 4.18 Hi-Tech Pharmacal: Revenue Breakdown by Business Segment (%), 2010

Figure 5.1 Actavis: Generic Revenues ($m), 2010-2015

Figure 5.2 Actavis: Generic Revenues ($m), 2016-2022

Figure 5.3 Fresenius SE: Revenue Breakdown by Company (%), 2011

Figure 5.4 Fresenius Kabi: Revenue Breakdown by Business Segment (%), 2010 

Figure 5.5 Fresenius Kabi: Revenue Breakdown by Region (%), 2011

Figure 5.6 Fresenius Kabi: Generic Revenues ($m), 2010-2015

Figure 5.7 Fresenius Kabi: Generic Revenues ($m), 2016-2022

Figure 5.8 Stada: Revenue Breakdown by Business Segment (%), 2010

Figure 5.9 Stada: Distribution of Costs (%), 2010

Figure 5.10 Stada: Revenue Breakdown by Region (%), 2010

Figure 5.11 Stada: Generic Revenues ($m), 2010-2015

Figure 5.12 Stada: Generic Revenues ($m), 2016-2022

Figure 5.13 Gedeon Richter: Ownership of the Company (%), 2012

Figure 5.14 Gedeon Richter: Revenue Breakdown by Business Segment, 2010

Figure 5.15 Gedeon Richter: Revenue Breakdown by Therapeutic Area, 2010

Figure 5.16 Gedeon Richter: Revenue Breakdown by Region, 2010

Figure 5.17 Gedeon Richter: Generic Revenues ($m), 2010-2015

Figure 5.18 Gedeon Richter: Generic Revenues ($m), 2016-2022

Figure 5.19 Krka: Revenue Breakdown by Business Segment, 2011

Figure 5.20 Krka: Revenue Breakdown by Region, 2010

Figure 5.21 Krka: Revenue Breakdown by Therapeutic Area, 2010

Figure 5.22 Krka: Generic Revenues ($m), 2010-2015

Figure 5.23 Krka: Generic Revenues ($m), 2016-2022

Figure 5.24 Russian Pharmaceutical Market: Segmentation (%), 2010

Figure 5.25 Leading Companies in the Russian Pharmaceutical Market: Market Share (%), 2010

Figure 5.26 Egis: Revenue Breakdown by Therapeutic Class, FY 2011 

Figure 5.27 Egis: Revenue Breakdown by Region, FY 2011

Figure 5.28 Orion: Revenue Breakdown by Business Segment, 2011

Figure 5.29 Orion: Revenue Breakdown by Region, 2011

Figure 5.30 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Volume (%), 2010

Figure 5.31 Turkish Pharmaceutical Market: Generic and Originator Products Share of Market by Revenue (%), 2010

Figure 5.32 Veropharm: Leading Prescription Drugs, Company Revenue Share (%), H1 2011

Figure 5.33 Veropharm: Traditional Products, Company Revenue Share (%), H1 2011

Figure 5.34 Veropharm: OTC Products, Company Revenue Share (%), H1 2011

Figure 5.35 Russia's Hospital Oncology Market: Leading Companies by Share (%), H1 2011

Figure 6.1 Ranbaxy: Revenue Breakdown by Region (%), 2010

Figure 6.2 Ranbaxy: Approvals and Filings by Region, 2010

Figure 6.3 Ranbaxy: Generic Revenues ($m), 2010-2015

Figure 6.4 Ranbaxy: Generic Revenues ($m), 2016-2022

Figure 6.5 Cipla: Export Revenues Breakdown by Region (%), 2010

Figure 6.6 Cipla: Generic Revenues ($m), 2010-2015

Figure 6.7 Cipla: Generic Revenues ($m), 2016-2022

Figure 6.8 Dr. Reddy's: Revenue Breakdown by Business Segment (%), 2010

Figure 6.9 Dr. Reddy's: Top Indian Generics Brands, Revenue Share (%) 2010

Figure 6.10 Dr. Reddy's: Revenue Breakdown by Region (%), 2010

Figure 6.11 Dr. Reddy's: Generic Revenues ($m), 2010-2015

Figure 6.12 Dr. Reddy's: Generic Revenues ($m), 2016-2022

Figure 6.13 Sun Pharma: Revenue Breakdown (%) by Business Segment, 2010

Figure 6.14 Sun Pharma: Indian Generics Revenue Breakdown (%) by Therapeutic Area, 2010

Figure 6.15 Sun Pharma: Cumulative ANDA Filings and Approvals, 2004-2011

Figure 6.16 Sun Pharma: Generic Revenues ($m), 2010-2015

Figure 6.17 Sun Pharma: Generic Revenues ($m), 2016-2022

Figure 6.18 Lupin: Breakdown by Business Segment, 2010

Figure 6.19 Lupin: Business Segment Share of Revenues (%), Lupin FY 2007-2011

Figure 6.20 Lupin: Export Markets Share of Revenues (%), Lupin FY 2007-2011

Figure 6.21 Lupin: Generic Revenues ($m), 2010-2015

Figure 6.22 Lupin: Generic Revenues ($m), 2016-2022

Figure 6.23 Wockhardt: Generic Revenues Breakdown by Region (%), 2010

Figure 6.24 Aurobindo: Generic Revenues Breakdown by Region (%), 2010

Figure 6.25 Aurobindo: Generic Drug Submissions and Approvals, Breakdown by Region (%), 2010

Figure 6.26 Zydus Cadila: Generic Revenues Breakdown by Region (%), 2010

Figure 6.27 Biocon: Revenue Breakdown by Business Segment, 2010

Figure 6.28 Strides Arcolab: ANDA Submissions and Approvals, Company FY 2005-2010

Figure 6.29 Glenmark: Revenue Breakdown by Business Segment (%), 2010

Figure 6.30 Glenmark: Generic Revenue Breakdown by Segment (%), 2010

Figure 7.1 Aspen Revenues Breakdown by Region (%), 2011

Figure 7.2 Aspen Revenue Growth by Region (%), 2011

Figure 7.3 South African Market by Company Share (%), June 2011

Figure 7.4 Aspen's Latin American Revenues: Breakdown by Country (%), June 2011

Figure 7.5 Aspen: Generic Revenues ($m), 2010-2015

Figure 7.6 Aspen: Generic Revenues ($m), 2016-2022

Figure 7.7 Hikma: Revenue Breakdown by Business Segment, 2010

Figure 7.8 Hikma: Revenue Breakdown by Region, 2010

Figure 7.9 Sawai: Revenue Breakdown by Therapeutic Class, 2010

Figure 7.10 Sawai: Revenue Breakdown by Sales Channel, 2010

Figure 7.11 Nichi-Iko Generic Portfolio: Breakdown by Formulation, 2010

Figure 7.12 Nichi-Iko AGR (%), Company FY 2001-2010

Figure 7.13 Towa Revenue Breakdown by Therapeutic Class (%), FY 2010

Figure 7.14 Nippon Chemiphar Generic Revenues as Share of Overall Revenues, Company FY 2007-2010

Figure 7.15 Brazilian Pharmaceutical Market by Segment, 2010 

Companies Listed AA Pharma

Abbott Laboratories 

Able Labs 

Abraxis Bioscience

Abrika Pharmaceuticals

Aceto Corporation

Actavis 

Active Pharma 

Adcock Ingram

Aegera Therapeutics

Alapis

Alcon

Alfred E. Tiefenbacher 

Almirall Prodesfarma

Alnylam Pharmaceuticals

Alphapharm

Alpharma 

Altra Investments 

Amerigen Pharmaceuticals

AmerisourceBergen

Amgen 

Amide Pharmaceutical

Amneal Pharmaceuticals

Amylin Pharmaceuticals

Anadys Pharmaceuticals

Ancraf

Andrx Corporation

Angelini

Angenerico

Apicore

ApoPharma

Apotex

APP Pharmaceuticals 

Aprogen

aRigen Pharmaceuticals

Arrow Generics 

Asahi Kasei Pharma Corporation

Ascent Pharmahealth 

ASKA Pharmaceutical

Aspen Group 

Aspen Pharma 

Astellas

AstraZeneca

Aurobindo 

AxiCorp Sapient Discovery 

B. Braun Melsungen

Balkanpharma

Barr Pharmaceuticals

Baxter Healthcare

Baxter International

Bayer

Bayer Yakuhin

Bedford Laboratories 

Beltapharm 

Biddle Sawyer Corporation

Bilim Pharmaceuticals 

Bioceuticals Arzneimittel

BioChimico

Biocon

Biogen Idec

biomo pharma 

Bioniche Pharma 

BioTech Pharma

BiotechCorp

Bioton

Biovail Laboratories 

Biovena Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bunker Industria Farmaceutica

Cadila Healthcare

Caraco Pharmaceutical Laboratories

Cardinal Health 

CareFusion

Celgene Corporation

Celltrion 

Center of Molecular Immunology (Cuba)

Cephalon 

Chattem Chemicals

ChemGenex

Chon Kun Dang 

Ciba-Geigy 

CIMA Labs

Cipla

Claris Lifesciences

Clinton Foundation

Cobalt Laboratories

Colotech 

Combino Pharm 

CoPharma

Corporacion Infarmasa

Covidien

CSC Pharmaceuticals

CSFB Alternative Capital

CVS Pharmacy

Dabur Pharma 

Daiichi Sankyo

Debiopharm

Delta Pharma

DepoMed

Dey Pharma

DoctorActive 

Dr. Reddy's Laboratories

DuPont Crop Protection

DURECT Corporation

EastPharma 

Ebewe Pharma

EBIK

Eden Biopharm

Egis Pharmaceuticals

Elan 

Eli Lilly 

Elpen Pharmaceutical

Elpharma

Emcure Pharmaceuticals

EMET Pharmaceuticals

EMS Sigma

Endo Pharmaceutical

Ethex Corporation

Eurodrug Laboratories

Eurofarma Laboratorios

European Central Bank

European Generic Medicines Association (EGA) 

European Medicines Agency (EMEA/EMA) 

Eximas

Fako Pharma

Faran Laboratories

Farmaprojects 

Federal Court of Canada

Fidia farmaceutici

Filaxis 

Fisiopharma 

Food and Drug Administration (US FDA)

Fougera

Fournier 

Fresenius Kabi 

Fresenius Medical Care

Fuso Pharmaceutical Industries

G&W Laboratories

Galderma

Gedeon Richter 

Genepharm Group 

Genericon Pharma

Genéricos Españoles

Genertec Group

Genesoft 

Genzyme

Germa Pharm 

GlaxoSmithKline

Glenmark 

Graceway Pharmaceuticals

Grindeks

Grünenthal

Grupo Azevedos

Gujarat Lyka Organics

Gyma

Health Canada

Helm Pharmaceuticals

Help

Helvepharm

Helvetia Pharma

Hexal 

Hikma Pharmaceuticals

Hi-Tech Pharmacal 

HLJ.Haerbin Phar

Hormosan Pharma

Hospira

HRA Pharma

Human Genome Sciences

Hungarian State Holding Company 

Hypermarcas 

Ibiopro Solutions

Impax Laboratories 

Institut National de la Santé et de la Recherche Médicale (INSERM, France

Institut Pasteur Korea

IntelliPharmaCeutics

International Monetary Fund 

Invent Farma

IPR Pharmaceuticals 

Italfarmaco

Itero Biopharmaceuticals

IVAX 

Janssen

Javelin Pharmaceuticals

Johnson & Johnson

JS.L.Y.G. Hengr

JS Yangzijiang

Jubilant Life Science

Kendall

Kent Pharmaceuticals

Ke Lun Group

Kern Pharma

Kiadis Pharma

Kobrek Pharmaceuticals 

Korea Research Institute of Bioscience and Biotechnology

Kowa Company

Krka

Kroger

KV Pharmaceuticals 

Kyorin Pharmaceutical

Labesfal 

Laboratoire Theramex

Laboratories Besins Iscovesco

Laboratorio Sanderson 

Laboratorio Teuto Brasileiro

Laboratorios Cinf

Laboratorios Kendrick

LaborMed Pharma

Lamda Detergent 

Lehigh Valley Technologies 

LG Life Sciences

Lotos Laboratories 

Lundbeck 

Lupin 

Madaus

Mallinckrodt

Masterleik

Matrix Laboratories

Mayne Pharma

McKesson Drug Company

Medco 

Medeva Pharma

Medimpex

Medis

Medley

Medochemie

Meiji Seika Pharma

Menarini 

Merck & Co.

Merck KGaA

Midlothian Laboratories

Millennium Pharmaceuticals 

Milmet Labs 

Mitani Sangyo 

Mitsubishi Tanabe Pharma 

MJ Pharma

MN Pharmaceuticals

Mochida Pharmaceutical 

Moksha8 Pharmaceuticals

Momenta Pharmaceuticals 

Multicare Pharmaceuticals

Mylan

Myrallis

Napp Pharmaceutical

Nellcor

neuraxpharm

Nichi-Iko Pharmaceutical Co. 

Nihon Chouzai 

Nippon Chemiphar 

Nippon Kayaku

Nordic Capital

Normon

Novartis

Novel Laboratories

Novo Nordisk

Nycomed 

Ohm Laboratories 

Optimer Pharmaceuticals

Orchid Chemicals & Pharmaceuticals

Orion

Ortho-McNeil-Janssen

Paddock Laboratories

Pangeo

Par Pharmaceutical 

Perlecan Pharma

Perrigo Company

Pfizer

Pharma Avalance

Pharma Dynamics

Pharmacia & Upjohn 

PharmaPack International

Pharmascience

Pharmstandard 

Phlox Pharma

Pinewood Laboratories

Piramal Healthcare Solutions

Pliva

Polfa Warszawa

Polifarma

Polpharma

Pozen 

Pradeep Drug Company

Prazzi-Donaduzzi 

Promius Pharma

Pronova BioPharma

ProStrakan

Purdue Pharma Products

Puritan-Bennett

Pymepharco

QRxPharma

Ranbaxy Laboratories

ratiopharm-Merckle Group

Rega Farma de Produtos 

Remedica

Rheoscience

Rhodes Technologies

Ribbon 

Richter-Helm Biologics

Rite Aid

Rivopharm

Robin Hood Holdings

Roche

Rohatyn Group

Ross Products 

Safety Syringes

Safeway

Sagent Pharmaceuticals

Salomon Levin and Elstein 

Samsung 

Sandoz

Sanofi

Santarus 

Sawai Pharmaceutical 

Schering-Plough

Schwarz Pharma

Sekisui Medical 

SeQuent Scientific 

Servier 

Shandong Luoxin PH

Shandong Ruiyang

Shandong Qilu

SH.Asia Pioneer PH

Shelys Pharmaceuticals

Shionogi Seiyaku Kabushki Kaisha

Sicor

Sindan 

SK Chemicals

Solvay Pharmaceuticals

Somaxon Pharmaceuticals

Sovereign

Spear

Spirig Pharma 

Stada Arzneimittel

Stiefel Research Australia

Streuli Pharma

Strides Arcolab 

Sun Pharma

Synageva

Synthon Pharmaceutica

Syrrx

Taiyo

Takeda

Taro Pharmaceutical Industries

Teuto

Teva Pharmaceutical Industries

Teva-Kowa Pharma

Three Rivers

Tolmar 

Towa Pharmaceutical

Triax Pharmaceuticals

Tris Pharma

UCB Manufacturing

Unimed Pharmaceuticals

United Nations (UN) 

University of Aberdeen

University of Athens

University of Missouri

University of Thessaly 

University of Tokyo

Valeant Pharmaceuticals

Valleylab

Velefarm 

Veropharm

Versapharm

Veterin

Vianex

Vinchem

Walgreens

Walmart 

Warner Chilcott

Watson Pharmaceuticals

West Ward

Winthrop 

Wockhardt

World Health Organization (WHO)

Wyeth

Zentiva

Zhejiang Chiral Medicine Chemicals

Zhuhai Lizhu Group

ZiO Zdorovje

Zydus Cadila 

Zydus Hospira Oncology 

To order this report:Generic Drug Industry: Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

More  

Market Research Report

Check our  

Industry Analysis and Insights

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.